Of note, our network pharmacology study, RNA-seq analysis and Nrf2 intervene experiments indicate that the Keap1-Nrf2 pathway is the predominant enriched pathway associated with the protective effects of CTS on AAA. The gene discussed is KEAP1; the disease is triple-A syndrome.